- Report
- July 2026
- 130 Pages
Global
From €4300EUR$4,750USD£3,690GBP
- Report
- May 2026
- 144 Pages
Global
From €3576EUR$3,950USD£3,069GBP
- Report
- January 2026
- 150 Pages
Global
From €3576EUR$3,950USD£3,069GBP
- Report
- October 2025
- 160 Pages
Global
From €2861EUR$3,160USD£2,455GBP
€3576EUR$3,950USD£3,069GBP
- Report
- October 2025
- 160 Pages
Global
From €2861EUR$3,160USD£2,455GBP
€3576EUR$3,950USD£3,069GBP
- Report
- February 2026
- 154 Pages
Global
From €4391EUR$4,850USD£3,768GBP
- Report
- November 2025
- 150 Pages
Global
From €4391EUR$4,850USD£3,768GBP
- Report
- January 2026
- 190 Pages
Global
From €4481EUR$4,950USD£3,846GBP
- Report
- January 2026
- 97 Pages
Global
From €3123EUR$3,450USD£2,680GBP
- Report
- January 2026
- 96 Pages
Europe
From €3576EUR$3,950USD£3,069GBP
- Report
- July 2025
- 387 Pages
Global
From €1206EUR$1,379USD£1,000GBP
- Report
- October 2020
- 182 Pages
Global
From €4435EUR$4,899USD£3,806GBP
- Report
- June 2025
- 379 Pages
Global
From €4481EUR$4,950USD£3,846GBP
- Report
- August 2025
- 154 Pages
Global
From €2399EUR$2,650USD£2,059GBP
- Report
- June 2023
- 237 Pages
Global
From €4481EUR$4,950USD£3,846GBP
- Report
- June 2025
- 151 Pages
Global
From €2693EUR$2,975USD£2,311GBP
€3168EUR$3,500USD£2,719GBP
- Report
- July 2023
- 114 Pages
Global
From €4210EUR$4,650USD£3,613GBP
- Report
- September 2023
- 110 Pages
Global
From €5386EUR$5,950USD£4,623GBP
- Report
- November 2024
- 110 Pages
Global
From €5386EUR$5,950USD£4,623GBP
- Report
- January 2024
- 163 Pages
Global
From €2263EUR$2,500USD£1,942GBP

The Artificial Pancreas is a medical device that uses biomaterials to regulate blood glucose levels in people with diabetes. It is composed of a continuous glucose monitor (CGM) and an insulin pump, which are connected to a computer algorithm that automatically adjusts insulin delivery. The Artificial Pancreas is designed to mimic the natural pancreas, which produces insulin in response to changes in blood glucose levels. The device is intended to reduce the burden of diabetes management and improve glycemic control.
The Artificial Pancreas market is growing rapidly, driven by increasing prevalence of diabetes, technological advancements, and increasing awareness of the benefits of the device. The market is expected to be further driven by increasing investments in research and development, and the introduction of new products.
Some of the key players in the Artificial Pancreas market include Medtronic, Johnson & Johnson, Insulet Corporation, Dexcom, Tandem Diabetes Care, and Bigfoot Biomedical. Show Less Read more